Drug Profile
Research programme: Pro-Erectile Project - Correvio Pharma
Alternative Names: Research programme: erectile dysfunction drugs - Correvio PharmaLatest Information Update: 21 May 2018
Price :
$50
*
At a glance
- Originator Cardiome Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 15 May 2018 Cardiome Pharma is now called Correvio Pharma
- 27 Mar 2003 Discontinued - Preclinical for Erectile dysfunction in Canada (unspecified route)
- 27 Jun 2001 Nortran Pharmaceuticals is now called Cardiome Pharma